MALVERN, Pa., Nov. 07, 2018 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT) announced today that Stephan Rietiker has been elected to BioTelemetry’s Board of Directors. Dr. Rietiker was most recently the Chief Executive Officer of LifeWatch AG, until it was acquired by BioTelemetry in August 2017.  Prior to becoming CEO of LifeWatch AG in 2014, Dr. Rietiker held executive roles at Roche, Boehringer Mannheim, Schering Plough, Covance and as CEO of Centerpulse (formerly Sulzer Medica).  Additionally, he has been an investor, executive and Board Member of several developmental-stage companies and has been a Senior Advisor to Brown Brothers Harriman’s M&A practice. Dr. Rietiker, a Swiss-US dual citizen, is a trained physician with a doctorate from the University of Zurich, Switzerland, and is also qualified to practice

Company’s Results Exceed Expectations Company Raises Full-Year Guidance MALVERN, Pa., Oct. 30, 2018 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the third quarter ended September 30, 2018. Quarter Highlights    Recognized quarterly revenue of $100.0 million, exceeding expectations    Exceeded 23% year over year revenue growth    Achieved 25th consecutive quarter of year over year revenue growth    Realized GAAP net income attributable to BioTelemetry, Inc. of $16.0 million, or 16.0% of revenue    Realized record quarterly adjusted EBITDA of $30.1 million, or 30.1% of revenue    Raising full-year revenue guidance to $397 to $400 million with an

MALVERN, Pa., Oct. 18, 2018 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2018 earnings on Tuesday, October 30 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Tuesday, October 30, 2018.  The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com.  If you are unable to participate during the live webcast, an archive will be available on our website for two weeks. About BioTelemetry BioTelemetry, Inc. is the leading remote and wireless medical technology company focused on delivery of health information to improve quality of life and reduce cost of care.  We provide cardiac monitoring, mobile blood glucose monitoring, centralized medical imaging, and original equipment manufacturing that

Company Delivers Record Results Raises Full-Year Guidance MALVERN, Pa., July 25, 2018 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the second quarter ended June 30, 2018. Quarter Highlights Recognized highest quarterly revenue in the Company’s history of $101.4 million Exceeded 14% year over year organic revenue growth Achieved 24th consecutive quarter of year over year revenue growth Realized GAAP net income attributable to BioTelemetry, Inc. of $10.4 million or 10.3% of revenue Realized record quarterly adjusted EBITDA of $29.1 million, or 28.7% of revenue Achieved $30.0 million of annualized synergies from the integration of LifeWatch with approximately $7.5

MALVERN, Pa., July 17, 2018 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT) will release its second quarter 2018 earnings on Wednesday, July 25 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Wednesday, July 25, 2018.  The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com.  If you are unable to participate during the live webcast, an archive will be available on our website for two weeks. About BioTelemetry BioTelemetry, Inc., formerly known as CardioNet, Inc., is the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care.  The Company currently provides cardiac monitoring services, original equipment manufacturing with a

MALVERN, Pa., June 13, 2018 (GLOBE NEWSWIRE) — (NASDAQ:BEAT) – BioTel CareTM (formally known as Telcare), a BioTelemetry company, announced today the release of its next-generation wireless blood glucose monitor for diabetes management. As an industry pioneer, BioTel Care developed the first FDA-cleared, cellular-enabled glucometer which supports real-time transmission and consolidation of patient data in an FDA-cleared cloud.  Building on the success of this technology, BioTel Care is launching its next-generation blood glucose monitor, which includes an innovative touch-screen user interface, enabling patients to easily test blood glucose levels while capturing additional personal health data.  The monitor’s remote capabilities allow patients to quickly communicate a wide range of relevant health information to their care providers.  Clinicians can access and track their patients’ data through the BioTel

Company Exceeds Revenue and Adjusted EBITDA Expectations MALVERN, Pa., April 25, 2018 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading mobile and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the first quarter ended March 31, 2018. Company Highlights Recognized highest quarterly revenue in Company’s history of $94.5 million Achieved 11% year over year organic revenue growth Achieved 23rd consecutive quarter of year over year revenue growth Recorded GAAP net income attributable to BioTelemetry, Inc. of $6.0 million Realized record quarterly adjusted EBITDA of $23.6 million, or 25.0% of revenue Realized approximately $7.0 million of synergies in the quarter from the integration of LifeWatch, on track to achieve

MALVERN, Pa., April 19, 2018 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT) will release its first quarter 2018 earnings on Wednesday, April 25 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Wednesday, April 25, 2018.  The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com.  If you are unable to participate during the live webcast, an archive will be available on our website for two weeks. About BioTelemetry BioTelemetry, Inc., formerly known as CardioNet, Inc., is the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care.  The Company currently provides cardiac monitoring services, original equipment manufacturing with a